Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Keunchil Park, Luis Paz‐Ares, Kenneth J. O’Byrne et al.|The Lancet Oncology|2016

Cited by 1.2k